These immune elements interact with tumor cells to influence the immunogenicity of tumors and their susceptibility to checkpoint inhibitors, including anti-Programmed cell death (PD-1) and anti-PD-L1 antibodies. This evidence concerns the gene PDCD1 and neoplasm.